LPTX Stock: Why It Significantly Increased Today

By Amit Chowdhry ● Sep 16, 2021
  • The stock price of Leap Therapeutics Inc (NASDAQ: LPTX) increased by over 27% during intraday trading today. This is why it happened.

The stock price of Leap Therapeutics Inc (NASDAQ: LPTX) – a biotechnology company focused  on developing targeted and immuno-oncology therapeutics – increased by over 27% during intraday trading today. Investors are responding positively to Leap Therapeutics announcing the presentation of updated positive data from the first-line cohort of the DisTinGuish study, a Phase 2a clinical trial evaluating Leap’s anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene’s anti-PD-1 antibody, and chemotherapy, in patients with gastric or gastroesophageal junction cancer (G/GEJ), at the European Society for Medical Oncology (ESMO) Congress. The company will host a conference call tomorrow to discuss preliminary results from the study.

Leap Therapeutics announced positive initial data from the DisTinGuish study on Monday, September 13, 2021 based on 25 G/GEJ patients enrolled in the trial that showed DKN-01 in combination with tislelizumab and chemotherapy as first-line therapy was well tolerated with compelling activity. And the results presented at the ESMO Congress today included additional patient data stratified by tumoral PD-L1 expression levels based on visually-estimated combined positive score (vCPS), showing that robust objective clinical responses can be achieved from this combination regimen independently of PD-L1 expression.


“Initial data from this trial have shown that patients with high levels of DKK1 expression, a group with a poor prognosis, had encouraging responses to treatment. The additional data presented today show evidence that not only is DKK1 a critical biomarker in predicting response to DKN-01 and tislelizumab therapy, but also that the combination can induce deep responses regardless of the patient’s PD-L1 status, including particularly poor prognosis patients with both low PD-L1 and high DKK1. Taken together, these are promising results for the combination therapy of DKN-01 with tislelizumab and chemotherapy in first line patients with gastric or gastroesophageal junction cancers.”

— Samuel Klempner, MD, Member of the Faculty at Massachusetts General Hospital Cancer Center and Harvard Medical School

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.